Entrepreneurship

1. Executive Summary

1.1 Project Overview

Byegerm is a human-centered intelligent POCT sentinel platform for respiratory pathogens. It integrates RPA-CRISPR/Cas12a molecular detection, a closed microfluidic test card, portable hardware, AI-assisted interpretation, and scenario-specific SOPs, enabling non-specialists to conduct rapid, multi-pathogen, interpretable, and actionable on-site screening in eldercare facilities, kindergartens, primary-care facilities, fever clinics, and CDC sentinel sites.

We do not position Byegerm as a replacement for laboratory PCR. Instead, it is an on-site complement that extends molecular-testing capability from central laboratories to frontline settings, allowing results to inform triage, isolation, referral, and public-health warning workflows earlier. Interviews with experts, including Dean Li Juan of Jilin University’s School of Public Health and specialists from the Beijing CDC Institute for Infectious CDC, repeatedly highlighted two needs: sample-to-result within 30 minutes, and one-test multi-pathogen screening that is both rapid and usable by non-specialists. Byegerm’s core specifications—a 25–30 minute sample-to-result time, an LoD of 200 copies/mL, and parallel screening for five pathogens—were designed backward from these real-world requirements.

The market window is substantial. The global POCT market was valued at approximately USD 31.1 billion in 2023 and is projected to reach USD 43.2 billion by 2026, representing a compound annual growth rate of about 11%. Within that market, infectious-disease POCT was approximately USD 11.4 billion in 2023 and is projected to grow at a 4.3% CAGR from 2024 to 2030. China’s POCT market has grown at nearly 20% annually over the past six years and is expected to exceed RMB 23 billion in 2025. To avoid untraceable claims such as ‘multiple sources agree,’ every market figure in this document is tied to a named third-party source: overall global and China POCT data from iResearch and Guolian Securities research reports; global infectious-disease POCT data from Allied Market Research; molecular POCT segment data from QYResearch; and cross-checks against annual reports from listed companies such as Wondfo Biotech and other industry estimates. The original source, base year, and scope for every figure are listed in §2.5.2, Table 2-2, and Figure 2-1, with links to the underlying reports supplied for review and audit in the final submission.

1.2 UVP — Unique Value Proposition

1.2.1 UVP Statement

Byegerm is an intelligent POCT sentinel testing platform for respiratory pathogens designed for eldercare facilities, kindergartens, primary-care facilities, fever clinics, and CDC sentinel sites. By combining RPA-CRISPR/Cas12a, a closed microfluidic test card, AI interpretation, and scenario-specific SOPs, it enables non-specialists to complete multi-pathogen screening within critical time windows and translate results into on-site triage, isolation, referral, retesting, and public-health warning decisions.

1.2.2 UVP Formula

We use the classic ‘For [target users]—who need [need]—our product is [category]—that provides [benefit]—unlike [alternative]—we enable [differentiator]’ framework, allowing any stakeholder to examine, validate, or challenge the value proposition:

1.2.3 Why Customers Would Choose Byegerm

The underlying reason for client selection is that it provides a combination of existing solutions that cannot be balanced in the speed-information-operability triangle. An antigen test can produce results within 15 minutes, but usually only covers a single target and has limited sensitivity; The central laboratory PCR can be as sensitive as 103 copies/mL, but it often takes 4-24 hours from delivery to results. Byegerm completes multi-pathogen parallel tests within 25-30 minutes, with a floor limit of 200 copies/mL and increases the degree of resistance of the host DNA to 100 times the background concentration common in the clinical matrix through magnesium acetic acid dripping and closed reagents in the response system - which means that, in the first case of fever, a nursing home can obtain a five-column result on influenza, the COVID-19, RSV, HMPV, and pneumocococcus during a midday break, without having to wait hours or even days.

In terms of unit price-value ratios, based on the typical cost structure of the existing IVD industry, a single antigen was detected at a cost of about $5-8 and a single project PCR of about $30-60; while multiple PCRs of respiratory tracts generally cost between 200-500 dollars. By size, the five-message material of Byegerm is measured and the target terminal price is expected to be anchored at a single level of $80-120 to enable it to establish a clear value belt position on "antigens, multiple PCRs".

1.3 Entrepreneurship Logic

The entrepreneurial logic of Byegerm can be summed up in one sentence: to translate the engineering capacity of iGEM synthetic biology into the capacity of the "field molecular sentry" that is most needed by the grass-roots public health system, but most difficult to build. This logic is supported by three layers.

First, the demand layer. Our clients found (detailed in chapter 2) that the true pain point of respiratory infections was not "quantified" but "timely measured, on-site and actionable". Second, the technical layer. The RPA Heat Increase, CRISPR/Cas12a signal amplification, closed microfluidic, AI interpretation of these four independently validated technologies were first integrated into a non-professional closed system. Third, the institutional layer. We use the NMPA II/III IVD registration path as the anchor for compliance, with both eldercare facilities and kindergartens as anchors for validation, with "Equipment Infiltration + Usage Repurchase + Data Services Subscribe" as commercial sustainable anchors for conversion of "one-time projects" into long-term operational infrastructure.

Commercially more critical is that, at this stage, the market for the detection of respiratory pathogens in China is still growing at more than 25 per cent per annum, but the in-house market has been divided by the head IVD depths of Roth, Yape, Dannach, BioMérieux, St. Vincent's Biology, and Dan's Genes; and the scene of the Grassroots + Institution is still blank. Byegerm's business logic is therefore not "Face-in-the-house PCR market", but "to get into unserviced out-of-house scenes and complete business closure during the PESTLE windfall."

2. Potential Customers and Unmet Needs

2.1 Problem Background

The challenge for respiratory infections is that it is both an individual health problem and an institutional management problem, and more so a public health problem. Influenza, RSV, COVID-19, hMPV and bacterial respiratory infections may be highly similar in early symptoms, but the subsequent treatment path is different: Some need to be segregated, some need to be referred, some need to be retested, some concern the rational use of antibiotics and some may trigger public health reporting.

The global burden of disease illustrates the magnitude of the problem. According to WHO, seasonal influenza causes about 1 billion cases per year, including between 3 and 5 million serious cases and between 290,000 and 650,000 respiratory deaths; Epidemiological studies also show that hMPV can cause a significant burden of hospitalization among children under 5 years of age and those over 65 years of age, but is chronically underestimated because of insufficient testing. According to our interview with Vice-President Kiirin, Vice-President of the College of Public Health of the University of Jilin, "the virus's combined bacterial infections are common, but the logic of treatment is completely different: bacterial infections require antibiotics, and viruses are not." This observation leads us directly to multi-target designs of 4+1 (influenza, COVID-19s, RSV, hMPV+ pneumococcal). [S1] [S2]

In nursing homes and kindergartens, this risk is further magnified. In the event of concentrated fever and coughing, institutional managers are often limited to conservative measures such as limiting visits, suspending class activities, notifying parents, concentrating on referrals or waiting for out-of-country testing. These measures, while prudent, may lead to operational stress, family anxiety and waste of medical resources. The director of a nursing home we visited said, "The common cold of an old man, if the cause of the disease is not identified in time, is likely to turn into respiratory infections on the entire floor within a week," which is the very starting point of our project.

Existing detection paths are clearly fractured in real grass-roots scenes. Antigen testing is fast enough and cheap enough, but often the amount of information is limited to support multi-pathogen diversion; Laboratories PCR are highly accurate, but relying on sample trans-shipments, professionals and laboratory equipment often cannot return results within key windows of site diversion. WHO also noted that other respiratory virus infections may be characterized by influenza symptoms, making clinical identification difficult; Although widely used in clinical settings, rapid diagnostic tests are generally less sensitive than RT-PCR and reliability is affected by conditions of use. [S1]

2.2 First Potential Customers

We divided the first potential clients into three categories. This classification is not based on industrial inertia, but on "the pain intensity of rapid multi-pathogen screening" - the stronger the pain, the higher the willingness to pay, the lower the resistance to deployment.

2.2.1 High-risk agency clients

Including nursing homes, kindergartens and nursing institutions. These scenes are densely populated, with older persons and children belonging to groups at high risk of respiratory infections, and managers need to quickly determine whether to isolate, refer, notify their families or adjust operational arrangements. According to the Ministry of Civil Affairs, Annual National Ageing Development Bulletin 2024, by the end of 2024, the population of persons aged 60 years and over had reached 310 million people, or 22.0 per cent of the total population, and had officially entered a medium ageing phase; the China Centre for Population and Development Studies projected that the population of older persons in 2025-2030 would grow by a net annual average of 3.09 million to 390 million. At the same time, the total number of places in the national pension service is planned to reach more than 9 million in 2025, and the size of the institutional pension market is expected to exceed 50 billion yuan. In our special questionnaire for 755 old-age care workers, the most high-frequency pain point is "the onset of fever without rapid diagnosis of pathogens". [S3] [S5]

(b) Data from the AIDS Counselling Service show that China's infant and child care market was 15,181 million yuan in 2024 and is expected to climb to 23,231 billion yuan in 2030. "A total of 4.5 places per 1,000 population for children under three years of age" is a hard indicator at the end of "1450". There is a strong institutional demand for "parent-explainable, reset" visual screening tools.

2.2.2 Primary care and fever clinics clients

These include community health service centres, primary health-care facilities and fever clinics in level II hospitals. These scenes require quick completion of the primary screening, easing the stress of access, reducing unnecessary waiting, and providing doctors with more pathogen-directed supporting information. In our interaction with the Director of Hospital Inspections, it was repeatedly stressed that "The equipment on the ground must be a fool's operation, and the results must be read intuitively, as shown by the red and green light, and that the one-time detection of various pathogens is important for identifying diagnosis and precision control" -- feedback that directly shapes Bygerm's red and green light UI and the Five Test Designs.

In the light of the system, the National Commission on Health and others, among others, provide guidance on the overall promotion of a strong district health community. (a) Make it clear that by the end of 2025, more than 90 per cent of the country's counties (municipalities) will have almost completed a close district medical community, with almost full coverage by 2027; This opens a clear procurement window for Byegerm ' s equipment in the district level diagnostic system. [S4]

2.2.3 Clients at public health posts

These include district and city-level CDCs, community posts and screening sites. Such clients are concerned not only with single tests, but with regional trends, abnormal concentrations and early warning. In our interview, the Deputy Director of the Beijing Institute for CDC and Infectious Diseases made it clear that "detection equipment cannot be an island of information, and result data should be easily and safely accessible to existing infectious disease surveillance networks to support real-time early warning, epidemic trend analysis and control decision-making. "This directly drives the data architecture of Bygerm, "De-sensitization aggregation-sitting."

The "Health China 2030" programme outlines the improvement of early warning mechanisms for the surveillance of infectious diseases" and the "establishment of a system for the prevention and control of infectious diseases at the port of entry for the intelligent monitoring of infectious disease messages worldwide", with precision quarantine; and the 2023 "Professional Medical Quality Control Indicators for Infectious Diseases (2023 edition) further calls for a qualitative test of the "pre-pre-pre-pre-pre-prevalence and positiveness of influenza pathologies for the use of anti-influenza drugs", making the "pre-pathological diagnosis, after-use drugs" institutionalized. This means that on-site molecular tests at the end of the outpost move from "optional" to "necessary". [S6] [S7]

Thus, the first round of Byegerm is not a general "market for all respiratory tests" but: eldercare facilities + kindergartens + primary care/fever clinics + prefecture-level CDC sentinel sites. This is the best combination of pain, accessibility and replicability.

2.3 Customer Discovery and IHP Evidence

Our clients found that the product was not market-packed after completion, but that it was integrated into Designing and Integrated Human Practices at an early stage. The table below summarizes the core client findings we have completed, and all figures and references can be traced back to original interview records in IHP Wiki.

These numbers answer the same question together: Bygerm is not "we want to do," but "they tell us we have to do."

2.4 Unmet Needs

Through clients, we have found that our decentralized feedback system has been translated into six categories of unmet needs. Each category has both the characteristics of "high pain" and "no existing scheme can cover".

On-site rapid decision-making needs: the agency needs to decide within minutes whether to isolate, refer or retest, rather than waiting for the results to be delivered.

Information needs for multiple pathogens: Respiratory symptoms are similar, but pathogens differ and management strategies vary. Single or low-level information detection is difficult to support fine-tuning diversion.

Non-professional operational needs: Care workers, teachers and grass-roots staff are not likely to receive the same complex training as those in the testing section, so the system must be simple, closed and oriented.

(b) Children may be afraid to swallow. Products must fit real users, not just laboratory personnel.

Boundary needs for biosafety and liability: Agency concerns about infectious waste, liability for miscalculation, interpretation of results and parent communication.

Public health data needs: CDC requires not just isolated detection results, but sentinel data that reflect trends and unusually high concentrations.

The six types of demand form a "demand-design" map, each of which corresponds to the specific engineering actions of Bygerm (which are carried out in chapter 3 in the context of chapter 3).

2.5 PESTLE Analysis

To judge the external opportunities and commercialization constraints of Bygerm, we use the PESTLE framework to analyse its macro-environment. In this section, we deliberately dismantle each dimension into a three-part "Specific Policy/Data - Business Meaning for Byegerm - Strategic Action", so that PESTLE is not a static description, but a basis for commercial judgement that can be subject to external audit.

2.5.1 Political (political and policy environment)

China ' s public health and primary health-care system is currently undergoing a structural expansion, with top-level policies opening the procurement window for grassroots POCT checkpoints:

The Programme Framework "Health China 2030" states: "To improve early warning mechanisms for the surveillance of infectious diseases" and calls for "the establishment of a system for the prevention and control of infectious diseases at ports of entry with a global intelligence system for the surveillance of infectious diseases, which is accurate and quarantined". [S6]

Close county medical community construction (2023) No. 41: Require that by the end of June 2024, province-wide roll-out is required, that by the end of 2025 more than 90 per cent of districts (municipalities) in the country will have been built up and will be covered in full by 2027, and that the county health insurance fund 's "Pay for Packing + Total Advance" mechanism will allow for a significant upward movement in district procurement decision-making and preference for on-site testing tools that reduce hospital/referral costs.

In 2025, priority was given to the Integrated Health and Hygiene Pilot Zone at the grass-roots level: village health homes and community health service centres were required to have full coverage of district hospital staff, to provide full coverage of children's common diseases, and to "do an old, old and small health management service" - the "old and young" is the beachhead market of Bygerm.

Specialized medical quality control indicator for infectious diseases (2023 edition): the inclusion of "pre-influenza pathogen diagnosis positive" in the medical quality control indicator, making "pre-diagnostic, post-infection" a physical constraint at the institutional level. [S7]

(b) The 15th Recommendation further clarifies the direction of the silver economy as a priority sector, which is expected to increase from 6% to 9% of GDP in 2035.

Business implications for Byegerm: Together, the policy constitutes a "basic rich, human, targeted and accountable" procurement environment. Byegerm does not need to bet on a new policy, but is able to "take a ride" into an open district medical community, an old and small health management, infectious disease quality control, and four procurement routes for surveillance of communicable diseases.

2.5.2 Economic (economic and market size)

In terms of market size, POCT and infectious disease molecule diagnosis have continued to show high growth over the past decade, and the break-in track that Byegerm enters is in the best commercial window of "large, high growth, low concentration, blank bandwidth":

Business implications for Byegerm: Bygerm does not need a gambling track growth, and the entire upstream track has entered double-digit growth with multiple drivers of policy, population, technology. But Byegrem can't use $8.4 billion for the SAM - a market that has been enriched by the blue sea of Roth, Yape, Dannach, BioMérieux, St. Vincent, the Daane Gene, Booch Cricket, Zhuang Huisheng, Helsch, etc.

Strategic Actions: Before § 3.6 SWOT, use the TAM/SAM/SOM three-layer funnel to anchor the market size as "the market we can really compete for" and avoid over-optimizing the size of the total market.

2.5.3 Social (social and demographic structure)

Deep ageing: According to the Ministry of Civil Affairs' 2024 National Bulletin on the Development of Ageing, 310 million people (22.0 per cent) were aged 60 years and over, and 220 million (15.6 per cent) were aged 65 years and above. The Centre for Population and Development Studies of China projects a net annual increase in the older population from 320 million to 390 million people and an ageing rate from 22.8 per cent to 27.7 per cent in 2025-2030.

(b) The size of the silver economy market reached 15.8 trillion yuan in 2025 (White Paper on the Silver Economy 2025).

(a) Structural needs for birth and care: In 2023, the number of newborns dropped to 9.02 million, but fertility policies combined with inclusive care programmes have reinforced the willingness to pay for the health of "minus and lean" children;

Urban and rural level consultations: The needs of district residents for "homeside testing" are highly correlated with the cost constraints of the county medical community's "total fee" - "lower referral, early diversion" is the core KPI for district administrators.

The commercial meaning of Byegerm is not only a policy slogan, but also a consumption-system composite market with clear capacity to pay, clear institutional entry, and clear regulatory pressure. Byegerm's "Ageer+Care" double-posted resonance with the social and demographic structure.

2.5.4 Technology (technology maturity and industrial chain)

(b) The 2024-2025 Review (PMC, etc.) indicated that the CRISPR + isothermal amplification (RPA/LAMP) had been achieved by ≤30 minutes, 10^2 copies/mL scale sensitivity to the next generation POCT technology. [S8] [S9]

microfluidic industrial chain nationalization: microfluidic materials and abbreviations such as PDMS, COP, COC have developed in the country a mature generation of industrial ecology (Shenzhen, Suzhou, Nimbardo ODM), and single-card BOM costs can be contained between 15 and 30 metrozones, making it possible to "hardware penetration plus repurchase" business models.

AI marginal interpretation hardware matures: AI SoC from Sichuan, Cold Wu, has supported the lateral YOLOv8 reasoning; cost of effort and price can be close to ARM Cortex-M level MMU.

Trends in multiple pathogen screenings: the integrated solution of the Manfon biorespiratory tract, Zhue Xianxiang, and the Zhue Xianxian Zhuong Zhui Zhuong Zhui Zhui Zhuong Zhui Zhui Zhui Zhui Zhui Zhui Zhui Zianhu Zhui Zhui Zhu Zhui Zianhu Zhu Zhui Zhui Zian Zhu Zhu Zhui Zian Zhu Zhu Zhu Zhu Zhu Zi reagent box are on the market, indicating that clinical recognition of multiple tests has been validated - this is an advantage for Bygerm to "pay the costs of education".

Business implications for Byegerm: It's not "can bet technology work," it's "for the first time we've integrated the technology that we can already use into the grass-roots scene." Technical risks have been mitigated early, but the integration and engineering risks remain self-sustaining (see § 3 and § 4.4 for details).

2.5.5 Legal (Law and compliance)

NMPA IVD Registration Path: Registered under the Measures for Registration and Recording of In vitro Diagnostic Reagents (Order No. 48 of the General Directorate of Market Supervision) and Medical Devices Registration and Recording (Order No. 47 of the General Directorate of Market Supervision), Category I, Category II/III. Byegerm Multiple Nucleic Acid Detection reagents for the V pathogen fall in categories II or III; Hardware equipment is also to be declared separately according to the medical equipment classification rules. [S11] [S12]

Registration cycle and cost: routine II for exemption from clinical trials The typical three project cycles are 1 to 1.5 years; Projects requiring clinical trials (multi-centres, more than 3 clinical institutions) are usually 2 to 3 years, and registered tests + clinical trials + the total cost of system verification is usually between 3 and 8 million yuan (industry experience).

Quality management system: The technical requirements for YY/T 0287-2017 (equivalent to ISO 13485) and for the production of medical devices (YY/T 0287 + GMP) and category III IVD products require that the main raw materials and production processes be identified in appendix form. [S13]

Data compliance: The Personal Information Protection Act, Data Security Act, Information Security Technologies, Health Medical Data Security Guidelines (GB/T 39725), together constitute a compliance base for health data; [S14] [S15] [S16]

Advertisement and declaration of boundary: under articles 16 and 18 of the Advertising Act and the Criteria for the Review and Publication of Medical Devices, the IVD product cannot claim to be "a substitute doctor's diagnosis"; Byegerm must use the term "preliminary screening/auxiliary" and retain clinical review. [S17]

For the commercial meaning of Byegerm: Compliance is not an ancillary process of "product formation and reprocessing" but rather a process from the design input stage, i.e. impact: 1) the selection of categories for registration, 2) the retention of processes and raw materials files, 3) the data architecture and privileges model, 4) the marketing of narratives and training content. Bygerm plans to introduce IVD registered consultants at the end of Phase I to synchronize the builder development document (DHF).

2.5.6 Environmental (Environment, Biosafety and ESG)

(b) The Medical Waste Management Regulation requires the central disposal of infectious waste within 48 hours, with significant compliance costs for grass-roots institutions. [S18]

ESG and procurement preferences: ESG ratings are being introduced in the procurement reviews of conglomerates, local state enterprises and some head-linking/care institutions; Light quantification, self-destruction, recyclable casings, low energy consumption designs are significantly more detailed.

Biosafety liability: The Biosecurity Act makes it clear that the institution is responsible for the entire process of infectious samples and waste, and that what is most feared at the grass-roots level is not the cost of testing, but the "misuse is being pursued".

Business implications for Byegerm: Environmental dimensions are not ethical requirements, but rather procurement subdivisions and liability risk buffers. Byegerm directs closed card boxes, in-situ self-destruction of sodium hypochlorate, modularized light transport, and standardized agreements with third-party medical waste disposal agencies into the SOP, which translates ESG and biosafety risk visibility into product differentiation points.

2.6 Market Sizing — TAM / SAM / SOM

In order to avoid over-optimizing the size of the market, we use the classic TAM/SAM/SOM three-layer funnel to further reduce the total market volume referred to in PESTLE to "the real contestable market of Bygerm".

2.6.1 TAM — Total Addressable Market

TAM is defined as the theoretical upper limit "if all relevant respiratory pathogen tests are completed in China 100% by Bygerm". Based on the projected scale of respiratory pathogen detection in the Chinese compound for 2028, about RMB 10,110 billion, the size of the Chinese infectious disease IVD 2027 about RMB 28 billion (20 billion x 1.098^4) and the estimates of out-of-home locations (alienage/care/grass-roots 5400 + 15,180,000 million spent on health) the TAM ceiling is as follows:

Calculator: TAM Byegerm, 2028 about $10.1 billion (in-house) + $3 billion (respiratory channels related to out-of-house posts) about $13 billion

2.6.2 SAM — Serviceable Addressable Market

SAM subsegregation of genuinely accessible Bygerm - Old Age Homes, Kindergartens/Cares, Primary Health Care (Community Health Services Centres + Town Health Centres), Secondary Hospital fever clinics, District and Municipal CDC Postes, and exclusion of the Centre ' s 3A Hospital PCR market. We're using the "number of institutions x annual frequency detection x unit price" to remodel from bottom up.

Estimated by conservative calibre (50% institutional end configuration rate, 0.5 screenings per person per year, single price of $100):

Calculator: SAM approximately (4,000 text million institutionally covered people) x 0.5 x 100 yuan approximately 20 text billion yuan/year

In 2028, the overall SAM was conservatively estimated at 2.5-4 billion yuan.

2.6.3 SOM — Serviceable Obtainable Market

SOM is the realistic market share of Bygerm in Phase III (2030-2032). Based on the typical five-year municipal share of IRD start-up companies, 1 to 3 per cent (references to early shares of target companies in the same period of time, e.g., Botonics, Zhuang Huisheng, etc.) and combined with the differential positioning and channel-building rhythm of Bygerm:

Calculator: SOM text2032 about SAM x (2% – 5%) about 0.5 – 2 text billion yuan/year

This zone is not "surprising" but it is enough to support a small batch of IDD start-up companies reaching a positive operating cash flow in Phaase III and constitute the valuation anchor for the next round of strategic financing.

From the bottom up, independent validation: § 5.6's financial model is not based on market aggregates, but is cumulative year by year with "a single annual card consumption x a single card terminal price" based on a baseline scenario of $52.06 million in operating income in 2032, or approximately $5.2 billion, just below the SOM zone. The two approaches are completely independent -- one from top to bottom, one from bottom to bottom, and one from bottom to bottom, and then to the same zone. This cross-certification indicates that SOM measurements are not too high and that the financial model takes a conservative end between SOM sectors.

2.6.4 Clarification as to why the three layers are decreasing rather than incremental

A common hunch in the review is that the TAM/SAM/SOM three tiers should be incremental, such as from the Jilin province to the national and international levels, and on a growing scale. There is a need to clarify a very confusing concept: TAM/SAM/SOM is a deliberately designed "value-drinking funnel", not a "geographic expansion ladder". The funnel answered the question "How much can we really compete at the same point in time (e.g. 2028) from the theoretical disk" and therefore inevitably decreases from one level to the next: TAM (about $13 billion, all related tests) ⊇ SAM (about $2.54 billion, outside the courtyard + serviceable part) ⊇ SOM (about 0.5 billion to 200 million dollars, a realistic share for start-ups over five years). Declining is precisely the purpose of this methodology -- to prevent the use of "large total market" to cover up "very little we can really get."

Intuitively, the incremental relationship between the "Gilin Province" and the "National International" is real, but it describes another dimension -- the expansion of geographical coverage at any time, corresponding to the three phases of the § 4.1 road map, rather than the market segment at the same time. In order to avoid confusion, we have translated this incremental geographical logic into a separate figure of 2-3: Byegerm, with Jilin province (group location, start-up outpost) as Phase I-II as the base for validation, copying to the Long Triangle, Kyouta, Chengzheng, and expanding the network of local and municipal outposts throughout the country, after 2032, to make international adaptations to low-resource areas such as South-East Asia and Africa. So the funnel decline is not in conflict with the "geographical increase," but the same business plan has two positive views on the "share dimension" and "geographic dimension."

3. Feasibility, Scalability and Inventivity

3.1 Scientific and Technical Feasibility

Bygerm's technical route revolves around "workable on site" rather than "highest laboratory complexity". Our interview with Professor X. Chris Le of the University of Alberta directly helped us to move from the original PCR approach to the RPA-CRISPR route - "It is feasible to use PCR in conjunction with CRISPR for scientific research in the laboratory, but your goal is to develop portable equipment at the port site, which is a completely different technical selection logic" - a sentence that determines the entire hardware shape of Byegerm.

In particular, the RPA constant isothermal amplification (37-42°C) makes nucleic acid expansion less heavily dependent on complex temperature-controlled cycles and more suitable for portable equipment and ground-level sites, with single expansions usually 15-20 minutes. CRISPR/Cas12a identifies the target sequence through crRNA and creates a signal magnification effect (trans-cleavage) after identification, providing a specific foundation for multi-pathogen detection. microfluidic detection cards integrate sample processing, augmentation, identification and signal output into closed channels, reducing the risk of manual transfer and contamination; We use array-style stand-alone small-room structures to control cross-pollution rates below 0.1%. AI interprets the image recognition of fluorescent signals through a light quantitative volume neural network based on YOLOv8, allowing non-professionals to also obtain standardized results.

Thus, the feasibility of Bygerm comes from four levels:

A bioreaction system is feasible: RPA and CRISPR/Cas12a are suitable for rapid molecular identification and have been validated in several literatures to achieve near PCR sensitivity in 30 minutes.

Engineering integration is feasible: microfluidic card boxes can reduce open operation and pollution risks, and third-party blinding batch mutations CV < 5%.

The process is feasible: App and SOP can guide non-professionals to complete the operation, and 89% of the IHP certifications have achieved a rating rate of 99% for the blind and 94% for the child.

Site deployment is feasible: portable equipment and closed materials are suitable for old age, child care, grass-roots medical care and outposts, and modular transport strategies support "dry and wet separation" to reduce cold chain costs.

3.2 MVP — Minimum Viable Product

Bygerm 's MVP is not a single device, but a minimum viable system: a one-time microfluidic card + portable interpretation device + AI App + SOP. One of these five components is missing -- any missing system is demo, which looks pretty but doesn't work.

This MVP is used to validate five key assumptions, each of which corresponds to specific indicators that have been or will be validated:

The goal of the MVP is not to achieve a full commercial product at once, but to validate the real scene with a minimum system that is "available, available, buyable, expandable".

3.3 Validation Strategy

Bygerm's verification is moving on three layers of "laboratory-availability-situation". These three layers are not parallel relationships, but funnel relationships: laboratory certifications are "can we run through", usability tests are "can we run through ordinary people", scene tests are proof that the agency can use it as a daily tool.

Laboratory Validation

Laboratory certification is used to demonstrate whether the detection system works. Wiki Add detection time, minimum test limits, specificity, cross-response, repetition, compatibility of different targets and signal interpretation stability. We have optimized the detection floor to 200 copies/mL in the buffer system;

Usability Validation

Validation of usability is used to demonstrate whether a true user can use it. Wiki shows the success of the caregiver completion process, feedback from older users on UI and slides, child acceptance of friendly samplers, non-professional understanding of the outcome interface, and implementation of waste disposal processes. The IHP phase sampled 102 elderly people, 50 children and 200 persons with a alpha-rehabilitation period, resulting in 89 per cent old people ' s rate of positive blindness, 94 per cent children ' s positive mood and 95 per cent full-screen recognition.

Scenario Validation

The scene validation is used to demonstrate whether Bygerm can be converted into a management value. Wiki shows how the results of the tests are used to reduce the time of diversion, how the isolation and referral process is developed in the eldercare facilities based on the results, how the kindergarten informs parents of the results and arranges for a review based on the results, how the results are used in primary screenings in primary health-care institutions, and how the disease management obtains trend signals through aggregated data. Two sentinel institutions (a nursing home and a kindergarten) are now embedding Byegerm into a routine morning screening and an abnormal emergency response process, confirming the viability of the "test-decision-action" closed loop.

3.4 Inventivity — What Makes Byegerm Different

Bygerm ' s creativity is not a single technology point, but a combination of innovation in technology, products, systems and public health logic. We have four levels to illustrate the irreplaceable nature of this combination.

Technical Inventivity

Bygerm integrates RPA-CRISPR/Cas12a with microfluidic closed card boxes, optical reading and AI interpretation to make molecular detection more suitable for on-site screening. Key innovation points at the technical level include: the closed tube response design (reference " All-in-One" approach on Nature Commissions, pre-packaging Cas reporter molecules in tubecapable microbages, released mechanically by pressure, with no open-cover operation at all), array space diversion (reference to CARMEN approach, avoiding multiple RPA quotations in the same tube, light quantitative interpretation model based on YOLOv8 (using AdamW Optimizer and L2 positive, 70/20/10 ratio of training validation tests). [S10]

Human-centered Inventivity

Instead of simply moving laboratory processes into boxes, we are redesigning the interactive approach based on feedback from older persons, children and caregivers:

Magnetic slurry caps: replaces a thin spin button, supports one-hand large motion opening, adapts to a weak or shaking patient;

The big-word contrast UI and the red green light show that 95% of the full-screen high saturated green (safe) or red (alert) colours are considered "the most desired design for fever."

Associated self-destruction and elimination: mechanical puncture of an inner sodium chlorate capsule when the slide lid closes, 92% of respondents say "automated sterilisation locks reduce the anxiety of transmission to their families".

System Inventivity

Bygerm is not a reagent box + instrument, but a system program for "Detecting + SOP + App + Data + Site Process". It connects the results directly to the agency management action, rather than staying on the demonstration of the results. This system innovation is reflected in the "early identification - fast disposal - strong synergy" process in eldercare facilities, as well as child-friendly testing in kindergartens embedded in the morning screening process.

Public-health Inventivity

Bygerm converts the results of a single test into data nodes for potential outposts. In the context of compliance, disaggregated desensitization data can serve to monitor regional trends, expanding products from "diagnosis tools" to "part of public health infrastructure". This innovation in the dimensions of public health was directly confirmed by the expert interview with the Beijing Institute for CDC and Infectious Diseases as "must" - "detection equipment cannot be an information island".

The above-mentioned four layers of creativity together constitute a differentiated moat of Bygerm. But the moat has to be replicated to be commercially meaningful.

3.5 Scalability

The scalability of Bygerm comes from both product structures and business models.

In product structures, samplers, detection cards, equipment, App and SOP can be reused in different scenarios. Different pathogens can expand according to customer needs, from basic respiratory tracts to more complex CDCs, Panel - technically, this only needs to replace the crRNA with the quote, and hardware and software need not be significantly modified.

In the business model, hardware equipment can be used as an entry point into the institutional scene, repurchases of reagents and consumables are tested, and income from the Apple Advanced functionality, data visualization, equipment maintenance and training services are generated. This complex model of "hardware penetration - repurchase of materials - subscription to services" is more suitable for long-term service and regional expansion than for selling only one-time equipment. In combination with typical data for the IVD industry, hardware sales are usually 35-45 per cent, materials-consuming-maorily, 55-70 per cent, SaaS/data subscriptions 70 per cent; Byegerm takes 40 per cent of equipment, 70 per cent of materials, and 87 per cent of data and services in the financial model (§ 5.6.1). This means that the overall Māori structure will improve year after year with the increase in the ratio of materials to services - the ratio of revenue from materials under the baseline scenario rose from 49.9 per cent in 2030 to 81.9 per cent in 2034 and the combined Māori ratio from 58.4 per cent to 68.1 per cent (see § 5.5 and § 5.6 for details).

Through channels, Bygerm can establish pilot cases of poles through direct marketing and cooperation, and expand coverage through regional distributors, CDC projects, medical communities and public health procurement. The Education chapter, which provides a unique "first-to-first-education-to-sell" channel for the cognitive preparation of clients in follow-up institutions, has established a general contact point with more than five categories of people in high demand and three categories of people with special needs -- a resource that most IVD start-ups do not have.

So, the typegerm extension path is not "immediately national," but rather: small-scale whistle-point validation, pole-replicating, regional channels to build multipathogens, panel extension, public health data networks.

3.6 Competing Landscape

Before entering SWOT, we used the standard competitive analysis framework to break the Byegerm competition into three categories of "direct rivals, indirect rivals, potential rivals" and avoid the abstraction of the threat in SWOT. The three categories of criteria are: the direct competitors provide a "field/rapid pathogen detection" value that overlaps highly with Byegerm; the indirect competitors meet the same needs in different ways ("know what pathogen"), but in different forms; and potential competitors are not currently on the tracks at the base, but are capable of sinking or cross-border entry at any time.

3.6.1 Direct and indirect competitors

Conclusion: The real rival of Byegerm is not the "head IVD giant" but the "no-do-do-do-do-do" status quo in the out-of-house market, which means the agency can only observe + report + wait for the results." It is a blue sea that is seriously undervalued but completely open.

3.6.2 Five-dimensional matching of five listed business associates

The competition analysis answers "we and who robs the customer", and the bid analysis answers another question: Companies that have completed this path have been exposed to financial structures. We have selected the Dar'an gene, Dean's diagnosis, Marvian life, Sanctuary, Novo Zan's five listed companies to form the marker pool, which is based on their statement of equity, review of responses to queries and public disclosure of periodic reports. It is important to note that the pool is not a collection of "business-renowned companies" but a puzzle: each of the five companies provides a reference only to one dimension of Byegerm, and none of them is sufficient to be the object of the target alone.

Four structural lessons were given to the marker pool, which were not a restatement of industry common sense, but directly rewritten the specific parameters in § 5.5 and § 5.6.

Lesson one: Māori rate structures determine business models, not vice versa. Māori splits between instruments and materials are a prerequisite for this model, not a business error, as demonstrated by the fact that the Māori ratio for PCT instruments usually falls below 30-45 per cent, with reagent consumption reaching more than 60 per cent. Any POCT project that tries to make money by selling equipment will fail - the higher the price of the equipment, the slower it is to be installed, the faster it is to determine the base of the reuse of materials. By doing so, Byegerm fixed the ratio of equipment to 40 per cent and established its orientation tool, with all profits to be borne by the materials and services.

Lesson Two: Accounts receivable are the real killers of the model of government and public institutions. The share of receivables in operating income diagnosed by Dean is consistently high. (a) Under DSO conditions of 180 days, an amount of approximately $0.49 per dollar of additional income is immediately taken into account; This effect is fully measured in § 5.6.4 and § 5.6.5 and its conclusion directly determines the scale and pace of § 5.4 financing.

Lesson three: Triple concentration is an essential element in reconciling audit and review. The concentration of suppliers (Dian diagnostics on a single upstream, Danian genetics on imported raw materials), regional concentrations (proximity of revenue within the province of Dian diagnostics) and product concentrations (single dependence on sacred species) exposes the same type of problems at three dimensions. For early projects, triple concentration is inevitable, and the question is not whether it exists, but whether there is a verifiable timetable for decentralization, which we place in § 4.4.2.

Lesson four: Event-driven income does not form the basis of valuation. St. Lucian and Nolan used "Cick" in their declarations. After the outbreak-related product's "literate disclosure of performance, this is in itself the answer given by the capital market: investors pay only for renewable income. Therefore, all three scenarios in § 5.6 are modelled on a regularized screening, without any increase in the outbreak; Epidemic peaks are treated in this model as top options rather than baseline assumptions.

3.7 SWOT Analysis

SWOT analysis helps us translate project strengths and weaknesses into concrete strategic actions. We deliberately paired every SWOT with a specific "strategic action" and added to the TOWS matrix so that SWOT was not static.

3.7.1 SWOT quadrant

3.7.2 TOWS Matrix

The SWOT quadrant alone is not enough to guide action - what really has commercial value is the TOWS matrix: to combine internal (S/W) and external (O/T) factors, with four types of implementable strategies.

3.7.3 Strategic selection and prioritization

The TOWS matrix gives four types of candidate strategy, but "all four" means no strategy. In combination with the judgement of §2.5 PESTLE "Four-to-one" and the reality of § 4.4 in the risk matrix "Registered risks, financial risks two-high" we have clearly prioritized the four types of strategies and selected the main strategies.

Summarizing the strategic choice of Byegerm, using SO as a spear, WO as a bridge, ST as a shield, WT as a base - using the combination of "technology + education + sentry SOP" in the policy window to capture the outdoor blue sea, and co-locate registration and clinical slabs with co-financing to maintain the defence and financial bottom lines with patents, data and milestones.

3.8 Protectability — IP and Open Strategy

Byegerm's intellectual property protection should revolve around "three hard and one soft" and be accompanied by an open source strategy consistent with the open spirit of iGEM.

Test system patents: RPA-CRISPR/Cas12a target group, response system optimization and multiple identification process.

Chip structural patents: microfluidic channels, pre-assembly reagents, sealed structures and self-destruct extinction modules.

Equipment structural patents: Heat control, optical testing, modularized slots and portable power.

Software and algorithmic assets: AI interpretation model, results classification algorithm, App interface and data processing logic.

From an IP asset valuation perspective, in the light of the valuation experience of the IVD Enterprise (Equivalent Technology Phase) over the same period, 3-5 core invention patents + 1-2 soft + 1-2 trademarks typically support the Angel Wheel valuation of $3,000 - $80 million. Bygerm plans to complete no less than three first-time applications for core patents in Phase I.

At the same time, as an iGEM project, the spirit of openness in science should prevail. (b) Basic SOP, science materials, non-sensitive app prototypes and training manuals are open sources; This strategy both protects Byegerm's living space as a business entity and allows the iGEM community to reclaim our human-centered design and educational resources.

There is also a pre-existing job that is easily ignored by the student team but which directly disrupts the transaction at all stages: confirmation of title. The inventions of student teams often involve the identification of job inventions, and rights holders may be school or mentor teachers rather than corporate subjects. We have established the recognition of ownership of job inventions, as well as the transfer or exclusive licensing of patents to companies, as matters that must be completed before the rotation of Pre-A, and have written into the Pre-A conditions of § 5.4, Table 5-4, Round Go/No-Go - which are the same as the risk of inquiry that is exposed to § 3.6.2 on the pool of "the undetermined right to cooperate in research and development".

After "do what" and "do what." And then we have to say "do what" -- this is Development Plans.

4. Development Plans, Milestones, Resources and Risks

4.1 Product Development Roadmap

We have divided the road map into three phases. At each stage, independent and measurable results are set, enabling donors and partners to judge progress at any point in time. Each stage also anchors "success KPI" and "reverse condition" and avoids scalding before, after.

Phase I — Validation｜2026–2027

The core objective is to complete prototype validation and site exploration. Key tasks include:

Completion of RPA-CRISPR/Cas12a testing system optimization (five target cross-response < 0.5%, detection floor 200 copies/mL).

microfluidic detection card prototype completed.

Creates an AI interpretation app first edition (YOLOv8 framework, multiple scene light adaptation).

(c) Conducting testing of the availability of nursing homes, kindergartens and primary health-care settings, expanding the sample to at least 500 real users.

Collection of expert opinions and feedback from potential clients, resulting in a new version of the demand file.

Completion of initial intellectual property layout (not less than 3 core patents).

Development of standardized SOP and training materials for docking with the 10+ science general package that has already been validated in the EDU chapter.

Collection of baseline data for single annual card consumption: records the number of test card sheets actually consumed per year per pilot equipment. This is the most sensitive and the only input variable in the financial model (§ 5.6.1), which must be measured on-site rather than documented, and which increases the consumption of calories from 350 to 620, bringing the balance of gains and losses from 490 to 276 in-service machines.

Phase KPI: Laboratory validation data integrity + MVP prototype + not less than 2 sentinel institutions piloting + 1 core patent admission + single annual card consumption baseline data available. Refuse condition: Test lower limits or cross-reactions are not met

Phase II — Translation｜2028–2029

The core objectives are engineering, small-volume production and preparation for registration. Key tasks include:

Optimizing the structure and equipment stability of the detection card and remodeling the shell in accordance with the plating process.

Establishment of small-volume production processes to connect 1-2 co-producers with IVD production qualifications.

Multi-centre validation with hospitals and CDCs (target not less than 3 clinical centres).

Preparation of NMPA Registered Testing, Clinical Evaluation and Quality System document, recasting R & D records as standard DHF.

Completion of supply chain dual-supplier strategy, establishment of domestic + international suppliers for key enzymes and chips, respectively, and dual-source certification of core enzymes.

Sign a three-year step price agreement for core enzymes. The assumption of single card BOM £30 is premised on the core enzyme lock price; if the lock price fails, the full cost structure of § 5.5.2 needs to be re-run.

More sentinel institutions were piloted to cover transclimate, rural and urban areas.

Establishment of a marketing, training and after-sale system.

Stage KPI: Small batch BOM cost £30/calculation + Good rate + 95% + Registered Test accepted + 1-2 MAC data from MAC hospitals + Core enzyme double-source certification and step price agreement set. Refusal condition: BOM or a bad rate of underachievement Delay registration and surrender and concentrate process optimization.

Phase III — Deployment｜2030+

The core objectives are regional expansion and ecological construction. Key tasks include:

Deployment of a network of outposts in more municipal areas, targeting 50+ sentinel institutions, using the generic calibration "in-service" rather than "cumulative delivery".

Extension of pathogen panel (e.g. addition of SARS class, new outbreak agent reserve Panel).

Establishment of public health data Dashboard, interfaced with the CDC/WHC system and made data services a stand-alone, renewable fee contract rather than a hardware grant.

Explore payment paths with health insurance, insurance, public benefit funds or government projects.

International cooperation and adaptation of low-resource areas (e.g., South-East Asia, African grass-roots POCT pilots).

Establishment of long-term ESG and medical waste management mechanisms.

Phase KPI: Regional Repurchase Rate 50% + Crossing the Gains and Loss Balance Line (276-490) with an installed machine + Net Cash Flow from Operating Activities (base scenario 2034) + Landing of at least 1 local-city CDC data interface + International Pilot 1-2 + Data Services Revenues 25%. The last one is not just an increase path: it's a valuation logic of "IVD materials manufacturing" to switch to "public health data infrastructure", meaning § 5.7.3.

4.2 Regulatory and Clinical Path

Bygerm is an in vitro diagnostic-related product and commercialization cannot bypass registration, clinical evidence, quality systems and data compliance. In accordance with the NMPA regulations for the registration of in vitro diagnostic reagents, the in vitro diagnostic reagents for category I are subject to record management and the in vitro diagnostic reagents for categories II and III are subject to registration management. Based on the properties of the multi-detection of the five pathogens, the Byegerm reagents are presumably in category II or part III; Hardware equipment is also required to be declared in accordance with the medical equipment classification rules.

From industry experience, class II exemption clinical pilot projects typically have a registration cycle of 1 to 1.5 years and class III contains clinical pilot project cycles of 2 to 3 years; the total cost of registration tests, clinical trials, system verification usually falls between 3 and 8 million yuan. This is the core source of § 3.7 Threats T3 and the hard-bargaining of § 5.4 sub-cycle financing.

Therefore, we are considering seven compliance actions simultaneously in the early stages of development:

Product Classification and Registration Path: At the prototype stage, the category is locked against the NMPA In vitro Diagnostic Reagent Classification Subdirectorate.

Registration requirements: Contact a national or provincial medical equipment testing facility at the end of Phase I.

Clinical evaluation or clinical trial design: combine multi-centre samples with real world data.

Real world data collection: Accumulation through sentinel compliance uplink mechanisms.

Quality management system: constructed in conjunction with the Standard for Quality Management of Production of Medical Devices by YY/T 0287-2017 (equivalent to ISO 13485). [S13]

Data security and privacy protection: compliance with the Personal Information Protection Act, the Data Security Act, and the Information Security Technologies Guide to Health Medical Data Security (GB/T 39725). [S14] [S15] [S16]

The medical institutions explain the boundary: in SOP, the treatment norms of "preliminary screening is subject to in situ review" are defined and the liability boundary is defined.

The proactive presentation of the compliance path suggests that Bygerm does not stop at proof of concept, but understands the true path of commercialization of medical products.

4.3 Required Resources

Bygerm push requires not only funding, but also technical, clinical, manufacturing, compliance and market resources.

4.4 Risk Matrix and Mitigation

We systematize the main risks by technology, registration, market, supply chain, finance, data ethics, environment by seven dimensions, and provide specific implementable mitigation actions for each type of risk. Each category of risk has a "probability x impact" rating that allows for location in the risk thermal matrix.

4.4.1 Seven types of risk and mitigation actions

The risk thermal matrix shows that the registered risk and the financial risk are both high and high and must be pre-empted. This is consistent with § 3.7 W1, W5 and T3, T4 in SWOT.

4.4.2 Triple concentration and verifiable decentralization schedule

§ 3.6.2 Lesson 3 points out that supplier concentration, customer concentration, regional concentration and product concentration are four sides of the same category of issues, and are also mandatory for the due diligence and registration review. For the early projects, concentration is the inevitable -- it's not about whether it's concentrated, it's about when and in what verifiable way. We wrote this schedule in advance and tied it to the Roadmap phase.

4.5 Why the Plan Is Realistic

Bygerm's plan is not "one step at a national level" but a phased, low-risk, evidence-driven path:

Validation of technology first, then validation of users; Access to sentry scenes, then replication of regional cases; Establishment of high pain point demonstration clients, then extension of channels and product lines. The need for funding at each stage is linked to the key assumptions that need to be answered at that stage - if the assumptions at one stage are not validated, we will stop expanding and revert to the previous phase. This "assumption-validation-upgrading" cycle is consistent with the commercialization of medical products and with the entrepreneurship encouraged by iGEM to move from proof-of-concept to real-world solutions.

5. Required Capabilities, Funds and Stakeholders

Questions answered in this section: Byegerm is not a work of students with only beautiful technical concepts, but has identified the capabilities needed to continue to develop (Capabilites), funds (Funds) and Stakeholder (Stakeholders) networks and has been able to gradually transform the iGEM prototype into a verifiable, registerable, deployable and sustainable on-site detection system. Our judgment is that Bygerm must adopt the eco-economies model of "Student Team Leading Early Validation + Specialists and Industry Partners complement critical competencies + sentinel clients verify values". This chapter is based on the "Capacity List - Team Strengths and Disadvantages - Stakeholder - Finance Motion - Business Model - Financial Projections - Return and Exit of Investment" and is based on the "Five Circle Four" model of § 5.3 as the hub, which allocates each of the tasks in chapter 4, Roadmap, each of the capabilities in § 5.1, each round of financing in § 5.4 and each of the revenues in § 5.5 to specific bearers. Of these, § 5.6 to § 5.8 is the financial base of this chapter: all projected values are derived from the parameter summary table of § 5.6.1, which can be fully recalculated by any reader, and we do not provide conclusions that cannot be reproduced.

5.1 Capability Map

Continuing to advance Bygerm requires seven core competencies. Each type of capability corresponds to the specific key tasks in Phase I-III, and also finds the principals in the § 5.3 "Five Rings Four" to avoid delinking the "capability list" from the "real division of labour".

The key to the above table is not to list capacity, but to show that each capacity is not presented in a suspense - either for a Roadmap phase or for a category of stakeholders or both. This makes Chapter 5 a "division map" of the first four chapters, not a new argument.

5.2 Team Strengths and Gaps

The greatest advantage of the Byegerm team is not a single-scientific capability, but the ability to connect the three lines of "synthetic biology technology - real scenario demand - commercial path". We have an interdisciplinary basis for synthetic biology, molecular testing, hardware design, software development, IHP research and business analysis that can link laboratory innovation to real scene needs. This integration capability has been demonstrated in three facts that can be validated externally:

Technical integration: Independent completion of the RPA-CRISPR route selection, multi-target reference design, AI interpretation model training and microfluidic chip modelling to form a demonstrationable end-to-end MVP.

Network of experts: Establish a "research-compliance-policy" feedback channel with testing, clinical, compliance and policy specialists from Zhejiang University, Jilin University, Alberta, etc.

Site coverage: In six categories of retirement homes, kindergartens, communities, hospitals, industry, and supervision, clients who have completed a user-industry system found that over 1,300 questionnaires were recycled and 30+ experts interviewed.

At the same time, we are conscious of the fact that health products need to move from the iGEM prototype to the real world, across the five thresholds of "scientific viability -- engineering stability -- clinical credibility -- regulatory compliance -- commercial sustainability." The student team cannot complete all five thresholds on its own, so the key is not "presumably full-fledged" but rather visible identification of gaps, visible allocation of resources, visible design of recent actions. The main current gaps and ways to fill them are as follows:

Thus, the organizational strategy of Byegerm is not "student team covers all the links", but rather uses the Build-Partner-Buy combination path: core algorithms, product definition and early validation by team Build; Clinical, regulatory, manufacturing and channel through partner; Legal, registration, quality systems and partial engineering tests are complemented by Buy's professional services.

5.3 Key Stakeholders — Five Rings and Four Flows

For Bygerm, stakeholders should not simply be understood as "all those who have heard of the project". We define stakeholders as individuals, institutions or organizations that can influence the success of the project or be affected by the use of products, data flows, resource allocation, risk-taking, at any stage of Bygerm from conceptual validation, MVP, clinical validation, registration, pilot deployment to scale operations.

To avoid being too broad or too narrow, we set three inclusion thresholds:

(c) Decision demand: Have decision-making power to purchase, access, clinical acceptance, regulatory approval, payment or promotion.

Value-use present: direct use of products, interpretation of results, action based on results, or health and management value from results.

Risk-afflicted risk of error, privacy, ethics, biosafety, costs, waste or public opinion.

Only subjects that meet at least one threshold and can provide demand, evidence, resources or constraints in product development are included in the Byegerm key stakeholder model.

5.3.1 Five Rings Model

We have integrated stakeholders into the Five Rings and Four Flows model. Five-ring represents the distance of different subjects from the core of product values - from the person served to the person deciding whether or not they can be served; The four-stream represents the key exchange that occurs between them - demand, evidence, product-service, governance-capital.

5.3.2 Four Flows

Need flow (demand flow): Import product definition from Ring 1-Ring 2.

Evidence flow (evidence stream): Remittance of product credibility from Ring 3.

Product-service flow: Output from Ring 4 to first-line scene.

Global Flow (Governance-Capital Flow) from Ring 5 project scale borders.

5.4 Funding Plan

Bygerm's scale of financing is not determined by "how much it takes to expand", but by "cash balances must not be negative at any point in time and a reasonable safety cushion should be maintained". The immediate consequence of this calibre is that the pace of financing is determined by § 5.6 cash flow forecasts, not by market ambitions. The use of each round corresponds to the key assumptions of chapter 4 Roadmap and corresponds to the key flows in the different rings in § 5.3, creating a milestone rhythm matching the "fund-risk-evidence".

5.4.1 Why four rounds and A?

Our original vision was three rounds: Seed Wheels 3-50 million, Pre-A Wheels 20-30 million, Series A 8,000-15 million. After the year-by-year input was placed in the cash balance sheet, two points had to be amended.

The first is rhythm. 2026-2029 for the Phase I-II input period, without commercialized income, with an annual investment of 380, 620, 1,450, 21 million yuan, totalling 45.5 million yuan. Of these, 2026-2027 totals about $10 million in two years, and three-and-five million seed wheels will form the funding cut-off point by the end of 2027. So we're going up to $7 million on the Seed round, and we're going to fill up the 8 million seed + wheel in 2027 -- which is not an easy bridge, without which the project will break at the end of the year.

The second is qualitative. (a) The size of the wheel should be pushed back by the accumulated cash gap (base scenario $83.35 million) and not by expansionary demand; This is one of the most intuitive parts of this chapter and the easiest to mislead investors -- we would rather write it in the eye of the body than want the investors to figure it out when they do it.

5.4.2 Validation of year-by-year cash balances

The following table is the only hard test of whether a financing plan has been established: any year-end cash balance is negative, and the arrangement does not exist.

The replacement of one-time large-value financing with "cut-off financing + gambling clause" is the core financial discipline of Bygerm to address the W5 financial burden and T3/T4 uncertainty in § 3.7 SWOT; the inverse scale of "no negative cash balances" gives the discipline the form of a value to be audited externally.

5.5 Business Model

The Byegerm business model can be summed up as: equipment entering the scene, waste materials repurchase, App and data services. It's a typical combination of "hardware penetration -- fuel repurchase -- service subscription."

5.5.1 Revenue Streams

Six income streams were condensed in the financial model into three business actions that could be actively intervened by the team, rather than an "annual growth rate". The core constant equation is:

Annual consumption material income = cost of a single card per unit per year

Annual equipment income = new installed units x unit cost of equipment for the year

Data and service income = (Equipment + Materials) x Service adhesion rate

Of these, the cumulative arithmetical averages of the "number of machines in use (annual average)" installed at the beginning and end of the period. The value of this modelling is that each variable corresponds to a specific action - the number of platform channels and the pilot drive, the annual calorie scenario SOP design and product accessibility, the single-card price matching pricing and collective negotiation; and the "income growth rate" does not correspond to any action, cannot be executed by teams or validated by investors. This is also why we have listed "single annual card consumption" as a level I indicator (§ 4.1).

5.5.2 Costa Structure and Pricing Logic

Pre-commercial inputs: hardware research and development, moulds, App development, registration declaration and quality system construction, for a total of approximately $45.5 million in 2026-2029 (§ 5.4).

Change cost: enzymes, crRNAs, probes, chips, samplers, packaging and logistics (target card BOM ≤30, subject to core enzyme lock price).

Compliance costs: Registered testing, clinical certification, third-party testing, ethical review (approximately $30-8 million, already included in pre-commercial inputs).

Market costs: Piloting, training, meetings, channel incentives and after-sales response, as reflected in § 5.6.3 for sales costs.

Pricing Logic: Lowering the threshold for entry of equipment to eldercare facilities, kindergartens and grass-roots institutions (free laying or leasing of equipment in the first year), establishing a stable cash flow (0.5 screenings per person per year x approximately $100 per single card) through repurchase of materials, providing data services, maintenance services and advanced reporting functions to clients of CDC and hospitals. Equipment is a diversionary tool, and waste materials and services are the source of profit - a division of labour that is not business-related, but rather a structural conclusion given by lessons learned.

The price reduction is a certain event rather than a risk event, as demonstrated by the price trajectory of the sacred species. So we have to figure out how much to lower the single-card terminal price with BOM fixed at 30. The following table is based on § 5.6 baseline scenario Data for 2034 (all 3,150 units per year are installed x 620 = 1953,000).

This table translates the characterization of "setting down price buffers for provincial IVD collections" into specific negotiable figures: From the current pricing of $100 to the 60% Māori rate target of $75, Byegerm owns 25% of the price reduction; from $75 to $46, the red line has 39% of the space, provided that the combined cost rate is simultaneously reduced to less than 30%. The dollar should be the starting point for cost justification in negotiations with the central authority - it is not an offer but an industry cost boundary based on BOM structure.

5.5.3 Unit Economics

Based on the five-year life cycle of a single device, annual customer loss rate of 15 per cent, steady annual calorie consumption of 560, the lifetime value of a single device (LTV) was 16.58 million yuan, of which 0.6 million yuan was contributed by equipment, 14.54 million yuan by materials consumed, and 1.45 million yuan by data services - 88 per cent by materials consumed. This ratio in itself suggests that the number of equipment sales is hardly independent in this model.

The LTV/CAC under the 3rd tranche CAC meets the thorium 3, and the recovery cycle is up to 1.3 years. But there is a fragile premise to this conclusion: an annual client loss rate of 15 per cent. If the institution fails to develop a usage habit after trial and the loss rate rises to 30%, the LTV will drop to approximately $1.19 million; Under CAC's early direct sale of $50.0 million, the LTV/CAC will fall to 2.4 and break the target line. So, "an institutional customer's 24-month retention rate of 60%" is not a good operational indicator, but a prerequisite for a unit economy to be established -- we add it to the "LTV/CAC 3" annual repurchase rate of 50% of the fuel-consumption ratio of 50%."

5.6 Financial Projections

5.6.1 Summary of modelling methods and parameters

All projections in this section are extrapolated from the following table, by which any reader can reproduce in full each of the values § 5.6 to § 5.7. The differences between the three scenarios are based only on installed rhythms and caloric consumption, with prices fixed at $100 in the three scenarios - this is intentional: prices are determined by the aggregate policy and are outside the control of the team, so uncertainty is placed on two variables that the team can influence, and the effects of price changes are borne separately by table 5-8. A description of the calibre is also required: all three scenarios are modelled on a regularized screening process, excluding any increase in the outbreak, the peak of which is treated as an upper option in this model.

5.6.2 Expected income

Revenue from commercialization has been recorded since 2030 (Phase III initial year). 2026-2029 is the input period for Phase I-II, with no commercialized income, and its cash impact is shown in tables 5-5.

The evolutionary path of the income structure itself is an indicator of the health of the business model: the share of consumption income rose from about 50 per cent in 2030 to 82 per cent in 2034, indicating that the installation has actually entered the daily work stream of the institution, rather than being left idle in the warehouse. If the consumption ratio does not work for a long time, even if the number of installed stations is pretty, it means that the product is not actually being used -- this is the first warning indicator for internal controls.

5.6.3 Cost paths for the period

In the IPO audit logic, "the risk of commercial bribery due to excessive sales costs" and "the lack of research and development inputs" are areas of serious concern. Cost structure projections require precision circumvention of these two mined areas, while avoiding underestimation of real costs for good reporting purposes.

An explanation is required for the start of the 18 per cent sales fee rate. It is true that open-source networks and public-interest sunk models can reduce traditional KOL maintenance costs, but here there are two types of costs: open-source networks reduce "market education costs" - to make institutional managers understand why multipathogen screening is needed on site. (b) It cannot reduce "channel maintenance costs and post-sale response costs" - equipment failure response, distribution of consumables, operational training refresher, quality complaints processing, which must be borne by its own team or channel partner. So we take up to 18 percent of the industry, and then we grow to 13.5 percent each year after the channel matures and repurchases. Such cost projections are closer to real operations and more affordable to pursue.

5.6.4 Three forecast statements

The three tables are cross-checked and the balance sheet has been balanced (the difference between "total assets" and "total liabilities and entitlements" for each year is zero).

The balance sheet revealed two key points. First, accounts receivable expanded from $3.12 million in 2030 to $117.6 million in 2034, accounting for 49.3 per cent of operating income and 55.8 per cent of total assets in the year - a proportion that is highly similar to the situation before Dean ' s diagnosis was put on the market and that is the subject of due diligence and scrutiny. Second, the undistributed profits were covered in 2034 by a negative correction (8297,000 yuan), i.e., cumulative losses; this point is material to subsequent declarations, as some of the listed routes have clear requirements for accumulated uncompensated losses.

Three tables were put together to see what was easy to ignore: The profit statement showed that the profits had been earned in 2030, the balance sheet showed that the accumulated losses had not been compensated until 2034, and the cash flow statement showed that the operating cash flow had not changed until 2034 and the free cash flow had not changed until 2035. The same company's three forms give three "go-time" points, four to five years. Looking at the profit statement alone leads to the wrong conclusion that "no more financing will be required after 2030" -- which is the most common miscalculation of the IRD early project, and is the direct basis for our characterization of Round A as "operating funds advances".

5.6.5 Balance of gains and losses, cash flow paradox and operating capital

Book balance: 276-490. Based on the fixed operating cost of 12 million yuan/year (comparable to approximately 35 people ' s team, quality system maintenance, registration maintenance and channel base inputs), the number of installed units in use to cover the fixed cost is as follows.

Here's a caliber that has to be made clear: the balance of gains and losses is determined by the use of "loading" instead of "cumulative drop" and the number of stations is heavily dependent on annual card consumption. If the consumption of cards rises from 350 to 620, the number of machines required to balance gains and losses will drop from 490 to 276, a 44 per cent reduction. § 3.6.2 This confirms the judgement of Lesson 1 - calorie consumption is a more critical operational indicator than the number of installed stations and a product design and scenario SOP should prioritize optimization.

The cash flow paradox: the faster the growth, the larger the gap. Under DSO conditions of 180 - 270 days, the amount of $0.49 - $0.74 per dollar of additional income is immediately taken into account; The increase itself consumes cash when the rate of increase is higher than the rate of repayment. The cumulative cash gap peaks in the three scenarios at $68.06 million (conservative), $83.35 million (baseline), $116.82 million (optimistic) - the better the business, the more financing is needed. This is not a model flaw, but rather a true pattern of testing of government and public institutions. Dean's diagnosis was directed to the same structure before the listing, the difference being that it was financed through IPO funding, and Byegerm had to cover the gap in the Pre-A and A rounds, or else it would fail with a high rate of income growth as a result of cash fractures -- the most typical growth death in the IVD industry.

Introduction of accounts receivable factoring, pushing DSO to 90 days, could release approximately $17.12 million in operating funds in 2032 and approximately $58.8 million in 2034; The annual cost of $4.7 million in exchange for the cash release of $58.8 million is a clearly cost-effective transaction under round A - this is why the financial cost rate is around 2 per cent in tables 5-10. The corresponding action was to pre-empt the signing point of the factoring framework to the Pre-A stage, rather than to wait for cash stress.

5.7 Investment Returns and Exit

5.7.1 Net present value and investment recovery Period

The cash flow sequence is: pre-commercial inputs in 2026-2029 (total - $45.5 million) + free cash flows in 2030-2034 + withdrawals in 2034 (in PS multiples of Table 5-10). The discount rate is set in five tranches to cover the required rates of return for different types of investors.

The three scenarios are positive under the overall five-tier discount rate, indicating that the project has an investment value within a reasonable risk pricing. But the absolute value of NPV is highly dependent on the exit-to-price assumption of 2034: under conservative scenarios, with a 30 per cent discount rate, NPV is only $23.71 million and the security margin is thin. This means that the feasibility of the exit path (§ 5.7.3) is more of concern than the NPV values themselves.

The same is true for the investment recovery period: from 2026 onwards, the static recovery periods for the three scenarios were about 8.1 years, 8.1 years, and 8.0 years, all of which occurred in 2034, and were achieved by withdrawal from the value of the price, rather than by operating cash flows. This is the same two formulations as the cash flow paradox of § 5.6.5 - the project remained in net cash consumption until the withdrawal occurred. The meaning for investors is clear: This is a typical exit-driven investment with no cash dividends in transit. It is more efficient for both parties to write this point in a business plan, rather than waiting for investors to figure it out themselves.

5.7.2 Intended rates of remuneration and returns in turn

By rotation (12 per cent Seed round, 8 per cent seed + wheel, 18 per cent Pre-Series A round, 22 per cent Series A round) and taking into account subsequent rotations, the returns for each round of investors when they exited in 2034 are as follows.

One thing must be clear to the A-wheel investors: in a conservative scenario, the A-wheel returns are 1.0 times, and IRR is about zero. This result should not be hidden; rather, it is the basis for the design of the investment clause - the A round has significantly higher downside risk than the earlier round, and there is a valid claim for liquidation priority, anti-dilution clause and performance bet. We will take the initiative in the negotiations to present this measure in exchange for a more reasonable valuation and easier repurchase trigger. Putting risks on the table would be far more advantageous than waiting for the other party to be counted.

At the same time, we have drawn three boundaries between the terms of gambling and repurchase:

The subject of the repurchase obligation is the company, not the founder, who bears unlimited joint and several responsibility. The individual solvency of the student start-up team does not cover the scale of Round A and acceptance of an unlimited chain of individuals is legally valid, but in reality constitutes a substantial destruction of the founders and an obstacle to subsequent financing.

Indicators of gambling should be tied to controllable matters. The number of data-service payment contracts for the completion of the Regional Repurchase Rate Targets is an impact that teams can influence by their efforts; and the "realization of net profits X million dollars for a given year" is dominated by the rhythm of the collection policy and fiscal disbursement and is not an appropriate indicator to trigger repurchases.

Repurchase triggers should have a remediation period and a phasing arrangement. The granting of a 6-12 month remedial window to the company and the granting of instalments to avoid single-point cash shocks would lead directly to the liquidation of the company, which would also be a better outcome for the investor itself.

5.7.3 Withdrawal mechanism

The exit path should be judged not on untested expressions such as "marketable in the future" but on the actual entry threshold for individual plates. The following table is based on the sample of enterprises (total of 64) processed in 2026 on the boards of the A shares.

Three conclusions that can be directly used: The board is the only one that substantially admits unprofitable enterprises (9 out of 15 samples) with the highest median amount proposed for fund-raising; The evidence threshold is lowest, but a profit is required, with a net profit of 51.12 million yuan in the sample and a median of 82.49 million yuan in the sample, with no loss; The empirical threshold for the board is between 200 million and 470 million yuan net profit, which is not realistic for Bygerm in the foreseeable time window.

We also need to see where Bygerm is in the non-profit medical enterprise. In 2025, a subset of medical devices and biomedicine in a sample of science boards accepted showed that the typical picture of unprofitable enterprises was: business income of 0.5 per 100 million yuan, annual net loss of 150 million yuan, and research and development personnel of 25 per cent per 36 per cent. This picture is fundamentally different from Byegerm, whose huge losses come from the capital consumption of clinical trials and the development of innovative medicines, while Bygerm ' s model is the early repurchase of materials that generate positive Maori, with losses much smaller than those of such enterprises and a lower income start than its financing tempo. In other words, Bygerm is in the middle of "not having a single-pound product that supports high market value, like a non-profit innovation drug, nor having significant absolute profits like a mature IVD company." This is the premise that exit path design must be addressed.

The honest conclusion is that, in three scenarios, Byegerm was unable to reach the market value level required by the non-profit standard of science and technology by 2034, or to meet the profit threshold of the board in a stable manner. So we have the exit from M&As as the baseline exit path, the preferred IPO path in the North, and the science board as the top path that requires additional conditions to trigger. It's more convincing to put this judgment in a business plan book than to write "The future will be on the board" -- the first is to say that the team understands capital market rules, the second is to say that the team has not checked the data.

What are the additional conditions to trigger the science panel path? In terms of valuation composition, the current pricing logic for Bygerm is "IVD materials manufacturing" (PS 3.5–6.5 times). To leap to a 4 billion-bit scale, the pricing logic needs to be changed to a "public health data infrastructure" -- which requires that the ratio of data to service income rises from 8 per cent to more than 25 per cent of the current model, and that data services result in independent renewable payment contracts rather than hardware grants. That's why we classified "Data Services at 25%" as level I KPI (§ 4.1): It is not just a gain path, it is a valuation logical switch.

5.8 Data classification, model limitations and commercialization closure Ring

To avoid secondary data contamination, we have a three-tier hierarchy of external data used in this chapter, and the financial model only allows the use of A and B data;

§ 5.5 to § 5.7 All of the figures produced by Bygerm itself are derived from the parameters of Table 5-10, which are fully recalculated endogenous data and do not rely on external references; The entries requiring external validation are concentrated in the two categories of operational data for the target company and listing rules, which we use as a basis for public disclosure documents by the Mega Tidal Information Network and the Exchange, with original links attached to the final submission. In particular, one of the listing rules is to point out that the third set of criteria for listing unprofitable enterprises and entrepreneurship boards has undergone several adjustments in recent years. Table 5-23, “Billion dollar market value scale”, is based on the approximation of general awareness and is updated in the original listing rules in force in the exchange prior to formal disclosure.

There are three limitations to the model itself, as we have indicated. First, the operating data of the five comparable companies are derived from their historical time and regulatory environment and are not fully comparable to the market conditions that Byegerm faces in the future; we use only its structural ratio and failure model and do not directly use its absolute values. Second, the full projection is based on the premise that the registration of evidence will be completed by 2030, and that if the registration cycle is significantly extended, the cash flow will move back as a whole, and the model will need to be re-run rather than simply extrapolated - it is estimated that every year the starting point for commercialization is postponed, the project IRR falls by about 8-12 percentage points. Thirdly, the threshold of the exit route is based on the accepted sample from 2025 to 2026 and the listing rules at that time, which must be verified before submission at the aforementioned calibre. These three limitations do not weaken the conclusions of this chapter, but define the scope of application of the conclusions - a financial projection that claims to be established under any condition is precisely the least credible.

The commercialization logic of Byegerm is therefore a complete closed loop: a list of competencies, team strengths and weaknesses, a five-ring four-stream division of labour, a milestone finance, a complex business model, a recalculated financial forecast, a clear exit path. Each section is not an isolated presentation, but a binding input for the next section; each resource requirement has a specific bearing, each fund has a verifiable release, and each number can be calculated by the reader using the same parameter table.

6. Long-term Impacts

6.1 Positive Long-term Impacts

The long-term impacts of Byegerm should be discussed among the target audiences and different stakeholders would benefit from the technology in different ways.

For Vulnerable Individuals

For the elderly and children, Bygerm can reduce unnecessary waiting, referral and oversegregation, and can reduce detection fear through more friendly sampling. This value has been quantified in our IHP certification - 94% of children who use the sampler do not show resistance, and 89% of the elderly give a good rating in blind operations that do not depend on sight.

For Care Institutions

For eldercare facilities and kindergartens, Bygerm can help managers to make quarantine, referral, notification of family members and retest decisions faster and reduce the operational pressure of one-size-fits-all seals. One of the concerns raised by the director of a nursing home that "a common cold has evolved into a whole floor infection within a week" was the specific pain that was to be overcome at the level of the Bygerm scene. From an institutional economic point of view, the cost of avoiding a building-level clustering of infections in terms of family compensation, closure, and repair of public opinion amounts to $500,000 per one-time, which constitutes a clear reason for Bygerm to pay for the retirement home.

For Healthcare Providers

For primary doctors and fever clinics, Bygerm can assist in the initial screening of respiratory infections, help to distinguish the risks of different pathogens, and provide a basis for rational use, referral and further examination. Considering that WHO classified anti-microbial drug resistance as a major public health and development threat and estimated that bacteria AMR had directly caused 1.27 million deaths and related deaths in 2019, 4.95 million cases were also of reasonable use of antibiotics to assist in field testing that distinguished viruses from bacterial infections. That was the central reason why Vice-President Koo suggested that we should include pneumococcus in 4+1 Panel.

For Public Health

Bygerm can be a more intensive and dispersed sentinel for the system. The consolidated compliance data help to detect anomalies earlier and support regional public health responses. In the long term, each of Bygerm's devices is a "distributive public health sensor" -- the ability of a single central laboratory to achieve no amount of additional flux.

For iGEM and Synthetic Biology

For the iGEM community, Byegerm demonstrates how synthetic biology projects move from laboratory prototypes to real social needs: rather than pushing technology to the market, it is constantly reshaping technology in client detection, expert feedback and accountability governance. We have settled the two-point technology transfer process, stakeholder interactions, and compliance model cases to iGEM Wiki in full, hoping to develop a similar focused scenario for the global iGEM team, providing a replicable paradigm that combines biosafety compliance, technical location effectiveness and multi-stakeholder synergies.

6.2 Potential Negative Impacts

Responsible innovation requires that we confront the potential negative effects of technology rather than show positive benefits. The main negative risks identified include:

Fake negatives lead to leakage: may create a false sense of security for institutions and families.

Hypothetical positives lead to over-reaction: they can trigger unnecessary containment, parental panic or waste of medical resources.

Data compliance risk: Insufficient sensitivity or unclear reporting paths may result in privacy disclosure.

Fuzzy boundaries of responsibility: Grass-roots institutions may make key decisions based on primary screening without medical confirmation.

Environmental burden: one-time materials increase the amount of medical waste.

Dependency risk: Institutions over-reliance on a single testing tool, neglecting other public health measures.

6.3 Governance and Mitigation

In response to the above-mentioned potential risks, Bygerm has established four-tier governance mechanisms:

Data Governance

Priority local encryption, desensitization before uploading, minimum necessity, clear authorization and withdrawal mechanisms; [S16]

Clinical Governance

(d) Standardized training certificate for primary care staff.

Operational Governance

The institutional side SOP is clear as to "what circumstances do not depend on Bygerm's results" - for example, severe disease recognition, prolonged bed rest, low immunization, etc., are still clinically judged.

Environmental Governance

(a) Closed card box + in-situ self-destruction + modular transport + note plastic mass production process, whereby the environmental footprint of the disposable material is controlled throughout the life cycle of the product;

6.4 Future Vision

Byegerm ' s long-term vision is not just to be a respiratory detection device, but to be part of grass-roots public health capacity.

In the short term, Byegrem will provide rapid multi-pathogen screening for nursing homes, kindergartens, primary care and fever clinics. In the medium term, Byegerm will be extended to CDCs, ports and regional public health networks, creating a more systematic trend monitoring capacity. In the long term, Byegerm can expand from respiratory pathogens to more infectious diseases, from single-point testing to a regional level, from equipment sales to an integrated service ecosystem of "test-data-training-public health response".

Ultimately, we want Byegerm to answer more than "how to detect a pathogen", but rather: how to really get synthetic biology into the grass-roots scene where it is most needed and increase social resilience in a affordable, manageable and sustainable way.

7. References

(1) Integrated Human Practices Wiki: Model for stakeholders, Power-Interest quadrant analysis, double-point construction records, full records of over 30 expert interviews, data on interactive tools for collaborative engineering (102 blinding old people, 50 child stickers voting, 200 retrospective questionnaires).

(2) Education Wiki: HEART-Edu Loop framework, high demand/sub-demand/special needs groups SOP, GitHub open source repository links.

(3) Project Design Design Design Design: RPA-CRISPR Five Targets Document, microfluidic Chip SolidWorks Model, Training Log for YOLOv8 Interpretation Model, Third Party Blindness Recurrence Report.

(4) Market and industrial data: Iri consulted China's PACT Industry Study 2024; QYResearch, Global and China's PACT Molecular Diagnosis Market Report 2025; Allied Market Research, Global Insurance Division Diagnostics Market 2019-2027; League of Nations Research Institute for Securities, Economics and Industry, Research in Respiratory Pathology Inspections; and AIDS consultant, China Infant Care Market Operation Data and Trends Report 2025-2026.

(5) Policies and regulations: "Health China 2030" Programme Framework; "XIV5" National Health Plan; "Guidance on the Comprehensive Promotion of Close District Health Community Building" (2023) (d) The Regulations on the Registration and Documentation of Medical Devices (General Directorate of Market Supervision Decree No. 47); [S4] [S6] [S7] [S11] [S14] [S15] [S16]

(6) Academic literature: CRISPR diagnostics overview (PM967495; PMC 10340307; ebiotrade 2026/01); DETECTR/SHERLOCK original literature series (Science 2018); CARMEN Multiple Testing Method (Nature 2020); CARMEN-Cas12a Array Space Flowing Principle (Nature Communications). [S8] [S9] [S10]

(7) Financial matching and capital market data: statement of account for the Da ' an gene (002030.SZ), Dian ' s diagnosis (300244.SZ), Manfu (300482.SZ), St. Vincent ' s (688289.SH), Novizan ' s (688105.SH), responses to queries and periodic reports (GTONET); [S19] [S20]

7.1 Authoritative sources and retroactive tables

The following table is used to trace new or reinforced factual statements. (a) Commercial measurement and team IHP data for market size should still be accompanied by the original report, questionnaire data sheets and interview minutes with the final submission;

The new financial and capital market component of this edition corresponds to two complementary sources: S19 - Public Disclosure Documents (Indications of Equity, Audit Query Responses, Periodic Reports) for the Corporation's Māori rate structure, cost rate, accounts receivable share and concentration; S20 - Public Information for the Distribution and Review of Public Information and the Existing Listing Rules of the Beijing Stock Exchange, for sample statistics and plate entry threshold determination. Both are A-level data as defined in Table 5-26 and are eventually submitted with the original link.